NCT04980638View on ClinicalTrials.gov

Intraamniotic Administrations of ER004 to Male Subjects With X-linked Hypohidrotic Ectodermal Dysplasia

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 26, 2022

Primary Completion Date

February 28, 2027

Study Completion Date

December 31, 2032

Conditions
X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)
Interventions
BIOLOGICAL

ER004

Intra-amniotic route 100 mg/kg of estimated fetal weight per injection. 3 injections, approximately 3 weeks apart starting from gestational week 26

Trial Locations (8)

20122

RECRUITING

IRCCS Ca' Granda Ospedale Policlinico, Milan

30120

RECRUITING

Hospital Universitario Virgen de la Arrixaca, El Palmar

63110

RECRUITING

Washington University, St Louis

75743

RECRUITING

Hôpital Necker - Enfants Malades, Paris

90048

RECRUITING

Cedars-Sinai Medical Center, Los Angeles

91054

RECRUITING

Universitaetsklinikum Erlangen, Erlangen

04103

RECRUITING

Universitaetsklinikum Leipzig AoeR, Leipzig

CF14 4XW

RECRUITING

University Hospital of Wales Cardiff and Vale University Local Health, Cardiff

All Listed Sponsors
collaborator

Pierre Fabre Medicament

INDUSTRY

collaborator

Iqvia Pty Ltd

INDUSTRY

lead

EspeRare Foundation

OTHER